Corvia Medical said today that a clinical trial of its Interatrial Shunt Device for treating heart failure met its primary endpoints at one year. Tewksbury, Mass.-based Corvia last November launched the Reduce LAP-HF II clinical trial ahead of a bid for FDA approval. The company’s IASD is designed to lower blood pressure in the left atrium and […]
Update: Corrected from previously mislabeled ‘interarterial’ to ‘interatrial’ shunts Corvia Medical said today it launched the Reduce LAP-HF II clinical trial of its transcatheter Interatrial Shunt Device designed to treat heart failure as it seeks FDA approval of the device. The Tewksbury, Mass.-based company said the 1st patient in the trial was enrolled by Dr. Rami Kahwash […]
Corvia Medical today released 1-year results from the Reduce LAP-HF clinical trial of its InterAtrial shunt device, touting a good safety profile and sustained device performance. Results from the 64-patient study was presented at the American Heart Association’s 2016 Scientific Sessions. The Tewksbury, Mass.-based company’s IASD is designed to lower blood pressure in the left atrium […]
Corvia Medical said today that it landed CE Mark approval in the European Union for its InterAtrial Shunt device for treating a type of heart failure. The IASD is designed to lower blood pressure in the left atrium and lungs by creating a small opening between the left and right atria. It’s indicated for diastolic heart […]
Corvia Medical said today that it won an investigational device exemption from the FDA for a clinical trial of its cardiac implant designed to treat diastolic heart failure and inked a deal with an unnamed strategic investor that includes an exclusive buyout option. Corvia’s transcatheter InterAtrial shunt device is designed to lower blood pressure in the left atrium […]
Corvia Medical, which is developing a cardiac implant designed to treat diastolic heart failure, yesterday said it raised a $34 million equity round. Tewksbury, Mass.-based Corvia said in a regulatory filing that 9 unnamed investors participated in the round, which logged its 1st sale in June 2014. The company, formerly known as DC Devices, closed a $10.7 million funding […]
Bay State startup DC Device announced the successful close of a $34 million Series D financing round, hoping to use the funds to advance clinical evaluation of its InterAtrial Shunt Device.
The company aims to market the world’s 1st minimally invasive device for treating diastolic heart failure, a market worth a potential $5 billion globally, according to a DC Device press release.
Massachusetts-based medical device startup DC Devices closed a $10.7 million funding round in support of its minimally invasive treatment for heart failure.
DC Devices "seeks to become the leading medical device company for the treatment of congestive heart failure," according to its page on the website of venture capital firm General Catalyst.